Premium
Fluorescein angiography patterns associated with the effect of intravitreal bevacizumab injection for diabetic macular edema
Author(s) -
KIM HS
Publication year - 2010
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2010.259.x
Subject(s) - medicine , ophthalmology , fluorescein angiography , diabetic macular edema , visual acuity , optical coherence tomography , bevacizumab , macular edema , surgery , diabetic retinopathy , diabetes mellitus , chemotherapy , endocrinology
Purpose To analyze the fluorescein angiography (FAG) findings associated with the effect of intravitreal bevacizumab injection (IVB) for treatment of diabetic macular edema (DME). Methods Seventy eyes of 65 patients with DME were included in this prospective, non‐randomized pilot study. The changes in best‐corrected visual acuity (BCVA) and central macular thickness (CMT) on optical coherence tomography were evaluated considering the FAG pattern at baseline and 3 month after IVB. Results On baseline FAG, 20 eyes (28.6%) showed honeycomb type hyperfluorescence; 9 eyes (12.9%), petaloid type; and 41 eyes (58.6%), diffuse type. Three months after IVB, the mean decrease in CMT was 250.5 (198.78) μm in the case of the honeycomb and petaloid type, which was significantly larger than that in the case of the diffuse type 102.5 (147.72) μm (p = 0.03). The improvement in BCVA was 0.27 (0.30) logMAR in the case of the honeycomb and petaloid type and 0.11 (0.27) logMAR in the case of the diffuse type; this difference was statistically significant (p < 0.02). There was no statistical relationship between the leakage starting time and CMT or BCVA. Conclusion The effect of IVB for treatment of DME was better in eyes showing honeycomb and petaloid type hyperfluorescence on baseline FAG than those exhibiting diffuse type hyperfluorescence.